US 10525106
Angiopoietin-based interventions for treating cerebral malaria
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 10525106 (Angiopoietin-based interventions for treating cerebral malaria) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/357